RNS Number : 7323U
Kromek Group PLC
11 August 2025

11 August 2025

Kromek Group plc
("Kromek" or the "Group")

New Biosecurity Award from UK MoD
Further CBRN Orders from Public and Private Organisations Globally

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, is pleased to announce that it has received a new biosecurity award from the UK Ministry of Defence ("UK MoD") as well as other orders in the CBRN Detection segment worth a total of c. £860k, with the majority to be delivered during the first half of the Group's current financial year to 30 April 2026.

The Group has received a contract from the UK MoD's Defence Science and Technology Laboratory, one of the principal government organisations dedicated to science and technology in the defence and security field, to develop novel methods of enhancing the detection of biological agents and incidents. The Group has been awarded £250k for the 18-month project, which is being funded through the UK Government's Defence and Security Accelerator.This complements Kromek's existing multi-year contracts for the development of biological-threat detection systems with a UK Government department and with the US Department of Homeland Security, and reflects the Group's strategy of undertaking customer-funded R&D in this area of activity.

Additionally, the Group has received several orders from global customers in the nuclear security segment as outlined below:

- The Group has received an order of $470k for its D5 detectors under a pre-existing Indefinite Delivery, Indefinite Quantity (IDIQ) contract, as announced on 25 April 2024, with a US federal entity for the provision of nuclear security products. To date, the Group has received orders of $1.9m under this IDIQ with up to $1.0m remaining to be ordered before the programme's expiry. This latest order is due to be delivered in the first half of the Group's current financial year.
- The Group has received three orders, totalling £252k, for the Group's D3M detectors from distributors for end customers in Japan, Canada and Bulgaria. The orders are for use by first responders and homeland security and are due to be delivered in the first half of the Group's current financial year.

Arnab Basu, Chief Executive Officer of Kromek, said: "These latest CBRN detection orders from both public and private sector customers across the UK, US, Japan, Canada, and Bulgaria underscore the global demand for our mission-critical solutions and the broad, growing base of organisations that rely on our technology. We are especially proud to have been awarded a new biosecurity contract by the UK Ministry of Defence, expanding our existing collaboration in nuclear security and reinforcing our position as a trusted partner in national defence. These orders provide increased visibility on our future revenue and reflect the strong momentum building in this segment. We look forward to reporting further progress as we continue to scale and deliver on our strategy."

Kromek Group plc
Arnab Basu, CEO +44 (0)1740 626 060
Claire Burgess, CFO

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance +44 (0)20 7220 0500
Tim Redfern - ECM
Michael Johnson - Sales

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble +44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the Advanced Imaging and CBRN Detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The Advanced Imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN Detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing biosecurity solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEANPEFFXSEFA